First human test for potential PNH treatment begins
NCT ID NCT06294301
Summary
This was the first study in humans to test the safety and basic behavior of a new drug called LP-005. It involved 68 healthy volunteers to see how their bodies handled single and multiple doses. The drug is being developed to treat a rare blood disorder called Paroxysmal Nocturnal Hemoglobinuria (PNH).
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Public Health Clinical Center
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.